Hartge P, Devesa S S, Fraumeni J F
Epidemiology and Biostatistics Program, National Cancer Institute, Bethesda, MD 20892.
Cancer Surv. 1994;19-20:423-53.
Incidence of HD varies from about 0.5 per 100,000 person-years in parts of Asia to over 3 in parts of North America. In recent decades, many registries have reported slightly declining age adjusted incidence among men and women. Some lymphomas previously diagnosed as HD now would be classified as NHL, but this shift does not explain all of the decline. When analysed by age group, incidence has decreased substantially at older ages, whereas increases have been reported among young adults in some industrial countries. Less developed countries continue to show high rates in childhood. Hodgkin's disease of the nodular sclerosis subtype has increased over time, whereas HD of mixed cellularity has declined. Improved therapy for HD has led to sharply declining mortality rates, but further understanding of the role of EBV and other possible causal agents should afford opportunities for prevention. Non-Hodgkin's lymphoma stands out from most other malignancies because incidence and mortality rates have risen dramatically, steadily and almost universally during the past few decades. Incidence overall has been rising 3-4% per year. No sudden rise has occurred in specific birth cohorts or calendar year of diagnosis, although incidence rates have increased more steeply at older ages. Diagnosis of NHL has improved with time, perhaps beyond the ways considered herein, but has it improved so much more than diagnosis of other malignancies, and roughly simultaneously around the world? Although it appears that diagnostic improvements are partly responsible for the upward trend, it is likely that aetiological factors are playing an important part. Infections with HIV have started to inflate NHL incidence rates further but cannot account for the striking trend already under way for several decades. Clues should be vigorously pursued to determine the role of other known viruses, immunosuppressive states, herbicides and other chemicals in the environment, and commercial products such as hair dyes. To clarify reasons for the upward trends and to take preventive action will require a better understanding of the origins of the lymphomas through epidemiological research, including interdisciplinary approaches that can identify new viruses, host-environmental interactions and lifestyle and other exposures that alter susceptibility.
霍奇金淋巴瘤(HD)的发病率在亚洲部分地区约为每10万人年0.5例,而在北美部分地区则超过3例。近几十年来,许多登记处报告称,经年龄调整后的发病率在男性和女性中略有下降。一些以前被诊断为HD的淋巴瘤现在会被归类为非霍奇金淋巴瘤(NHL),但这种转变并不能解释所有的下降情况。按年龄组分析时,老年人群的发病率大幅下降,而在一些工业化国家,年轻成年人中的发病率有所上升。欠发达国家儿童中的发病率仍然很高。结节硬化亚型的霍奇金病随时间增加,而混合细胞型HD则有所下降。HD治疗的改善导致死亡率急剧下降,但对EB病毒和其他可能病因的进一步了解应为预防提供机会。非霍奇金淋巴瘤与大多数其他恶性肿瘤不同,因为在过去几十年中,其发病率和死亡率急剧、持续且几乎普遍上升。总体发病率每年上升3%-4%。虽然老年人群的发病率上升更为陡峭,但在特定出生队列或诊断的历年中并未出现突然上升。随着时间的推移,NHL的诊断有所改善,可能超出了本文所考虑的方式,但它的改善是否比其他恶性肿瘤的诊断好得多,并且在全球范围内大致同时发生呢?虽然诊断的改善似乎部分导致了上升趋势,但病因因素可能也起着重要作用。感染艾滋病毒已开始进一步抬高NHL发病率,但无法解释已经持续了几十年的显著趋势。应积极寻找线索,以确定其他已知病毒、免疫抑制状态、环境中的除草剂和其他化学物质以及染发剂等商业产品所起的作用。为了阐明上升趋势的原因并采取预防措施将需要通过流行病学研究更好地了解淋巴瘤起源,包括跨学科方法,这些方法可以识别新病毒、宿主-环境相互作用以及改变易感性的生活方式和其他暴露因素。